JP2011517548A - 抗ｍｃｐ−１抗体、組成物、方法及び使用 - Google Patents

Info

Publication number

JP2011517548A

JP2011517548A JP2010515209A JP2010515209A JP2011517548A JP 2011517548 A JP2011517548 A JP 2011517548A JP 2010515209 A JP2010515209 A JP 2010515209A JP 2010515209 A JP2010515209 A JP 2010515209A JP 2011517548 A JP2011517548 A JP 2011517548A

Authority

JP

Japan

Prior art keywords

mcp

antibody

human

cells

binding

Prior art date

2007-06-29

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title claims abstract description 153
• 239000000203 mixture Substances 0.000 title claims abstract description 92
• 150000007523 nucleic acids Chemical class 0.000 claims abstract description 67
• 102000039446 nucleic acids Human genes 0.000 claims abstract description 62
• 108020004707 nucleic acids Proteins 0.000 claims abstract description 62
• 239000013598 vector Substances 0.000 claims abstract description 60
• 241001465754 Metazoa Species 0.000 claims abstract description 38
• 230000009261 transgenic effect Effects 0.000 claims abstract description 15
• 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 254
• 230000027455 binding Effects 0.000 claims description 164
• 241000282414 Homo sapiens Species 0.000 claims description 145
• 239000003814 drug Substances 0.000 claims description 68
• 229940079593 drug Drugs 0.000 claims description 66
• 239000012634 fragment Substances 0.000 claims description 65
• 230000000694 effects Effects 0.000 claims description 57
• 150000001413 amino acids Chemical class 0.000 claims description 52
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 50
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 40
• 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 38
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 33
• 210000000056 organ Anatomy 0.000 claims description 28
• 238000004519 manufacturing process Methods 0.000 claims description 25
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 19
• 239000003085 diluting agent Substances 0.000 claims description 16
• 102000004127 Cytokines Human genes 0.000 claims description 15
• 108090000695 Cytokines Proteins 0.000 claims description 15
• 239000005557 antagonist Substances 0.000 claims description 15
• 239000003795 chemical substances by application Substances 0.000 claims description 14
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 12
• 230000003302 anti-idiotype Effects 0.000 claims description 11
• 229940088597 hormone Drugs 0.000 claims description 11
• 201000000050 myeloid neoplasm Diseases 0.000 claims description 11
• 239000005556 hormone Substances 0.000 claims description 10
• 229920001184 polypeptide Polymers 0.000 claims description 10
• 210000003169 central nervous system Anatomy 0.000 claims description 9
• 238000000338 in vitro Methods 0.000 claims description 9
• 230000002526 effect on cardiovascular system Effects 0.000 claims description 8
• 239000002246 antineoplastic agent Substances 0.000 claims description 7
• 210000003403 autonomic nervous system Anatomy 0.000 claims description 7
• 238000001727 in vivo Methods 0.000 claims description 7
• 235000016709 nutrition Nutrition 0.000 claims description 7
• 238000007920 subcutaneous administration Methods 0.000 claims description 7
• 206010025323 Lymphomas Diseases 0.000 claims description 6
• 150000001875 compounds Chemical class 0.000 claims description 6
• 238000007918 intramuscular administration Methods 0.000 claims description 6
• 238000007912 intraperitoneal administration Methods 0.000 claims description 6
• 238000001990 intravenous administration Methods 0.000 claims description 6
• 238000007914 intraventricular administration Methods 0.000 claims description 5
• 238000004806 packaging method and process Methods 0.000 claims description 5
• 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 claims description 4
• 210000001124 body fluid Anatomy 0.000 claims description 4
• 239000010839 body fluid Substances 0.000 claims description 4
• 239000003792 electrolyte Substances 0.000 claims description 4
• 239000002955 immunomodulating agent Substances 0.000 claims description 4
• 229940121354 immunomodulator Drugs 0.000 claims description 4
• 230000002924 anti-infective effect Effects 0.000 claims description 3
• 239000003937 drug carrier Substances 0.000 claims description 3
• 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
• 238000011065 in-situ storage Methods 0.000 claims description 3
• 239000003860 topical agent Substances 0.000 claims description 3
• 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 claims description 2
• 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 claims description 2
• 210000001638 cerebellum Anatomy 0.000 claims description 2
• 230000009137 competitive binding Effects 0.000 claims description 2
• 102000054751 human RUNX1T1 Human genes 0.000 claims description 2
• 230000002207 retinal effect Effects 0.000 claims description 2
• 210000000278 spinal cord Anatomy 0.000 claims description 2
• 230000000241 respiratory effect Effects 0.000 claims 2
• 239000002550 vasoactive agent Substances 0.000 claims 2
• 210000001072 colon Anatomy 0.000 claims 1
• 229940125697 hormonal agent Drugs 0.000 claims 1
• 238000007913 intrathecal administration Methods 0.000 claims 1
• 230000037317 transdermal delivery Effects 0.000 claims 1
• 230000001225 therapeutic effect Effects 0.000 abstract description 10
• 101100504320 Caenorhabditis elegans mcp-1 gene Proteins 0.000 abstract description 2
• 210000004027 cell Anatomy 0.000 description 241
• 102000000018 Chemokine CCL2 Human genes 0.000 description 227
• 108090000623 proteins and genes Proteins 0.000 description 116
• 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 72
• 102000046768 human CCL2 Human genes 0.000 description 69
• 239000000427 antigen Substances 0.000 description 68
• 238000003556 assay Methods 0.000 description 66
• 108091007433 antigens Proteins 0.000 description 64
• 102000036639 antigens Human genes 0.000 description 64
• 239000000243 solution Substances 0.000 description 56
• 235000001014 amino acid Nutrition 0.000 description 55
• 229940024606 amino acid Drugs 0.000 description 50
• 230000014509 gene expression Effects 0.000 description 50
• 102000004169 proteins and genes Human genes 0.000 description 49
• 235000018102 proteins Nutrition 0.000 description 48
• -1 attract neutrophils Proteins 0.000 description 42
• 238000004091 panning Methods 0.000 description 40
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 38
• 206010028980 Neoplasm Diseases 0.000 description 37
• 241000699666 Mus <mouse, genus> Species 0.000 description 34
• 210000001519 tissue Anatomy 0.000 description 33
• 238000010367 cloning Methods 0.000 description 32
• 230000005764 inhibitory process Effects 0.000 description 31
• 201000010099 disease Diseases 0.000 description 30
• 239000013604 expression vector Substances 0.000 description 30
• 108060003951 Immunoglobulin Proteins 0.000 description 29
• 102000018358 immunoglobulin Human genes 0.000 description 29
• 102100034871 C-C motif chemokine 8 Human genes 0.000 description 28
• 239000011230 binding agent Substances 0.000 description 28
• 238000009472 formulation Methods 0.000 description 28
• AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 28
• 239000002953 phosphate buffered saline Substances 0.000 description 28
• 101710155833 C-C motif chemokine 8 Proteins 0.000 description 26
• 102100023688 Eotaxin Human genes 0.000 description 26
• 235000014113 dietary fatty acids Nutrition 0.000 description 26
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 26
• 229930195729 fatty acid Natural products 0.000 description 26
• 239000000194 fatty acid Substances 0.000 description 26
• 108020004414 DNA Proteins 0.000 description 25
• 239000000872 buffer Substances 0.000 description 25
• 238000002474 experimental method Methods 0.000 description 24
• 239000013612 plasmid Substances 0.000 description 24
• 102000005962 receptors Human genes 0.000 description 24
• 108020003175 receptors Proteins 0.000 description 24
• 238000011282 treatment Methods 0.000 description 23
• 102000019034 Chemokines Human genes 0.000 description 21
• 108010012236 Chemokines Proteins 0.000 description 21
• 230000004071 biological effect Effects 0.000 description 21
• 230000008569 process Effects 0.000 description 21
• 239000000047 product Substances 0.000 description 21
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 20
• 208000027418 Wounds and injury Diseases 0.000 description 20
• 238000005516 engineering process Methods 0.000 description 20
• 230000035800 maturation Effects 0.000 description 20
• 230000003472 neutralizing effect Effects 0.000 description 20
• 238000012216 screening Methods 0.000 description 20
• 230000009824 affinity maturation Effects 0.000 description 19
• 238000012512 characterization method Methods 0.000 description 19
• 102100032366 C-C motif chemokine 7 Human genes 0.000 description 18
• 206010052428 Wound Diseases 0.000 description 18
• 229920001223 polyethylene glycol Polymers 0.000 description 18
• 102000040430 polynucleotide Human genes 0.000 description 18
• 108091033319 polynucleotide Proteins 0.000 description 18
• 239000002157 polynucleotide Substances 0.000 description 18
• 101710155834 C-C motif chemokine 7 Proteins 0.000 description 17
• 238000004458 analytical method Methods 0.000 description 17
• 230000001976 improved effect Effects 0.000 description 17
• 101710139422 Eotaxin Proteins 0.000 description 16
• 230000035605 chemotaxis Effects 0.000 description 16
• 230000009260 cross reactivity Effects 0.000 description 16
• 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 15
• 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 15
• 102220548557 Macrophage-capping protein_V41I_mutation Human genes 0.000 description 15
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
• 241000699670 Mus sp. Species 0.000 description 14
• 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 14
• 239000002904 solvent Substances 0.000 description 14
• 241000588724 Escherichia coli Species 0.000 description 13
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 13
• 150000004665 fatty acids Chemical class 0.000 description 13
• 210000004962 mammalian cell Anatomy 0.000 description 13
• 238000005259 measurement Methods 0.000 description 13
• 229960000485 methotrexate Drugs 0.000 description 13
• 238000003199 nucleic acid amplification method Methods 0.000 description 13
• 238000005457 optimization Methods 0.000 description 13
• 239000000546 pharmaceutical excipient Substances 0.000 description 13
• 102000004497 CCR2 Receptors Human genes 0.000 description 12
• 108010017312 CCR2 Receptors Proteins 0.000 description 12
• 102100040247 Tumor necrosis factor Human genes 0.000 description 12
• 230000003321 amplification Effects 0.000 description 12
• 239000002299 complementary DNA Substances 0.000 description 12
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 12
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 12
• 229910052737 gold Inorganic materials 0.000 description 12
• 239000010931 gold Substances 0.000 description 12
• 210000001616 monocyte Anatomy 0.000 description 12
• 229920000642 polymer Polymers 0.000 description 12
• 239000000843 powder Substances 0.000 description 12
• 238000003653 radioligand binding assay Methods 0.000 description 12
• 230000001105 regulatory effect Effects 0.000 description 12
• 102100023702 C-C motif chemokine 13 Human genes 0.000 description 11
• 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 11
• 238000002965 ELISA Methods 0.000 description 11
• 241000196324 Embryophyta Species 0.000 description 11
• 239000002202 Polyethylene glycol Substances 0.000 description 11
• 229960002685 biotin Drugs 0.000 description 11
• 239000011616 biotin Substances 0.000 description 11
• 238000006243 chemical reaction Methods 0.000 description 11
• 238000009396 hybridization Methods 0.000 description 11
• 239000012212 insulator Substances 0.000 description 11
• 239000002609 medium Substances 0.000 description 11
• 238000002360 preparation method Methods 0.000 description 11
• 239000003755 preservative agent Substances 0.000 description 11
• 230000000717 retained effect Effects 0.000 description 11
• 238000006467 substitution reaction Methods 0.000 description 11
• 238000013518 transcription Methods 0.000 description 11
• 230000035897 transcription Effects 0.000 description 11
• 101710112613 C-C motif chemokine 13 Proteins 0.000 description 10
• 108010082548 Chemokine CCL11 Proteins 0.000 description 10
• 101000946794 Homo sapiens C-C motif chemokine 8 Proteins 0.000 description 10
• 229920001213 Polysorbate 20 Polymers 0.000 description 10
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
• 235000020958 biotin Nutrition 0.000 description 10
• 239000003623 enhancer Substances 0.000 description 10
• 230000006870 function Effects 0.000 description 10
• 230000001965 increasing effect Effects 0.000 description 10
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 10
• 102100024746 Dihydrofolate reductase Human genes 0.000 description 9
• 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 9
• 241000700159 Rattus Species 0.000 description 9
• 102220500147 Target of EGR1 protein 1_Y13A_mutation Human genes 0.000 description 9
• 210000003719 b-lymphocyte Anatomy 0.000 description 9
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
• 230000000295 complement effect Effects 0.000 description 9
• 230000000875 corresponding effect Effects 0.000 description 9
• 108020001096 dihydrofolate reductase Proteins 0.000 description 9
• 238000010494 dissociation reaction Methods 0.000 description 9
• 230000005593 dissociations Effects 0.000 description 9
• 102000043805 human CCL8 Human genes 0.000 description 9
• 210000004408 hybridoma Anatomy 0.000 description 9
• 208000014674 injury Diseases 0.000 description 9
• 239000003446 ligand Substances 0.000 description 9
• 239000003550 marker Substances 0.000 description 9
• 108010087904 neutravidin Proteins 0.000 description 9
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 9
• 230000033300 receptor internalization Effects 0.000 description 9
• 230000002829 reductive effect Effects 0.000 description 9
• 238000004448 titration Methods 0.000 description 9
• 230000004614 tumor growth Effects 0.000 description 9
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
• 241000894006 Bacteria Species 0.000 description 8
• 241000283707 Capra Species 0.000 description 8
• 108091026890 Coding region Proteins 0.000 description 8
• 241000282412 Homo Species 0.000 description 8
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 8
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 8
• 108010076504 Protein Sorting Signals Proteins 0.000 description 8
• 108010090804 Streptavidin Proteins 0.000 description 8
• 239000003242 anti bacterial agent Substances 0.000 description 8
• 208000006673 asthma Diseases 0.000 description 8
• 230000000903 blocking effect Effects 0.000 description 8
• 239000011575 calcium Substances 0.000 description 8
• 238000001514 detection method Methods 0.000 description 8
• 206010012601 diabetes mellitus Diseases 0.000 description 8
• 239000007924 injection Substances 0.000 description 8
• 238000002347 injection Methods 0.000 description 8
• 230000003993 interaction Effects 0.000 description 8
• 230000001404 mediated effect Effects 0.000 description 8
• 230000002335 preservative effect Effects 0.000 description 8
• 238000011160 research Methods 0.000 description 8
• 239000007790 solid phase Substances 0.000 description 8
• 239000000126 substance Substances 0.000 description 8
• 239000000725 suspension Substances 0.000 description 8
• 238000012360 testing method Methods 0.000 description 8
• 238000002560 therapeutic procedure Methods 0.000 description 8
• 239000003053 toxin Substances 0.000 description 8
• 231100000765 toxin Toxicity 0.000 description 8
• 108700012359 toxins Proteins 0.000 description 8
• 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 7
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
• 229920002307 Dextran Polymers 0.000 description 7
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 7
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
• 108091028043 Nucleic acid sequence Proteins 0.000 description 7
• 102220492441 Selenoprotein V_F43Y_mutation Human genes 0.000 description 7
• 206010052779 Transplant rejections Diseases 0.000 description 7
• 238000007792 addition Methods 0.000 description 7
• 229910052791 calcium Inorganic materials 0.000 description 7
• 239000006285 cell suspension Substances 0.000 description 7
• 230000001684 chronic effect Effects 0.000 description 7
• 208000035475 disorder Diseases 0.000 description 7
• 230000004927 fusion Effects 0.000 description 7
• 210000004602 germ cell Anatomy 0.000 description 7
• 238000011534 incubation Methods 0.000 description 7
• 230000007246 mechanism Effects 0.000 description 7
• 239000000178 monomer Substances 0.000 description 7
• 239000012071 phase Substances 0.000 description 7
• 230000008488 polyadenylation Effects 0.000 description 7
• 208000011580 syndromic disease Diseases 0.000 description 7
• 238000003786 synthesis reaction Methods 0.000 description 7
• 230000003612 virological effect Effects 0.000 description 7
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
• 102000001902 CC Chemokines Human genes 0.000 description 6
• 108010040471 CC Chemokines Proteins 0.000 description 6
• 241000701022 Cytomegalovirus Species 0.000 description 6
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
• 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 6
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 6
• 101000978392 Homo sapiens Eotaxin Proteins 0.000 description 6
• 108091006905 Human Serum Albumin Proteins 0.000 description 6
• 102000008100 Human Serum Albumin Human genes 0.000 description 6
• 206010020751 Hypersensitivity Diseases 0.000 description 6
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 6
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 6
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
• 108700019146 Transgenes Proteins 0.000 description 6
• 230000003213 activating effect Effects 0.000 description 6
• 239000000556 agonist Substances 0.000 description 6
• 230000033115 angiogenesis Effects 0.000 description 6
• 230000000692 anti-sense effect Effects 0.000 description 6
• 238000004166 bioassay Methods 0.000 description 6
• 230000001275 ca(2+)-mobilization Effects 0.000 description 6
• 201000011510 cancer Diseases 0.000 description 6
• 230000008859 change Effects 0.000 description 6
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 6
• ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 6
• 230000000147 hypnotic effect Effects 0.000 description 6
• 230000003053 immunization Effects 0.000 description 6
• 230000000670 limiting effect Effects 0.000 description 6
• 125000005647 linker group Chemical group 0.000 description 6
• 230000003211 malignant effect Effects 0.000 description 6
• 239000000463 material Substances 0.000 description 6
• 108020004999 messenger RNA Proteins 0.000 description 6
• 230000035772 mutation Effects 0.000 description 6
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
• 210000000440 neutrophil Anatomy 0.000 description 6
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 6
• 239000002245 particle Substances 0.000 description 6
• 239000008194 pharmaceutical composition Substances 0.000 description 6
• 230000002685 pulmonary effect Effects 0.000 description 6
• 239000000523 sample Substances 0.000 description 6
• 238000001542 size-exclusion chromatography Methods 0.000 description 6
• 239000011780 sodium chloride Substances 0.000 description 6
• 102100021935 C-C motif chemokine 26 Human genes 0.000 description 5
• 208000024172 Cardiovascular disease Diseases 0.000 description 5
• 108010083698 Chemokine CCL26 Proteins 0.000 description 5
• 102000053602 DNA Human genes 0.000 description 5
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
• 206010016654 Fibrosis Diseases 0.000 description 5
• 108010029961 Filgrastim Proteins 0.000 description 5
• 241000124008 Mammalia Species 0.000 description 5
• 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 5
• 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 5
• 208000012902 Nervous system disease Diseases 0.000 description 5
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 5
• 206010035664 Pneumonia Diseases 0.000 description 5
• 239000004793 Polystyrene Substances 0.000 description 5
• 239000007983 Tris buffer Substances 0.000 description 5
• 241000700605 Viruses Species 0.000 description 5
• 239000000654 additive Substances 0.000 description 5
• 239000000443 aerosol Substances 0.000 description 5
• 235000004279 alanine Nutrition 0.000 description 5
• 208000026935 allergic disease Diseases 0.000 description 5
• 238000013459 approach Methods 0.000 description 5
• 230000015572 biosynthetic process Effects 0.000 description 5
• 150000001720 carbohydrates Chemical class 0.000 description 5
• 235000014633 carbohydrates Nutrition 0.000 description 5
• 238000002983 circular dichroism Methods 0.000 description 5
• 230000001419 dependent effect Effects 0.000 description 5
• 231100000655 enterotoxin Toxicity 0.000 description 5
• 210000003527 eukaryotic cell Anatomy 0.000 description 5
• 238000011156 evaluation Methods 0.000 description 5
• 239000000284 extract Substances 0.000 description 5
• 108010074605 gamma-Globulins Proteins 0.000 description 5
• 230000012010 growth Effects 0.000 description 5
• 229920001477 hydrophilic polymer Polymers 0.000 description 5
• 208000015181 infectious disease Diseases 0.000 description 5
• 239000011859 microparticle Substances 0.000 description 5
• 201000002528 pancreatic cancer Diseases 0.000 description 5
• 230000036961 partial effect Effects 0.000 description 5
• 229920001282 polysaccharide Polymers 0.000 description 5
• 229920002223 polystyrene Polymers 0.000 description 5
• 238000000159 protein binding assay Methods 0.000 description 5
• 239000002287 radioligand Substances 0.000 description 5
• 230000009467 reduction Effects 0.000 description 5
• 150000003839 salts Chemical class 0.000 description 5
• 210000002966 serum Anatomy 0.000 description 5
• 238000002741 site-directed mutagenesis Methods 0.000 description 5
• 241000894007 species Species 0.000 description 5
• 235000000346 sugar Nutrition 0.000 description 5
• 239000006228 supernatant Substances 0.000 description 5
• 230000008733 trauma Effects 0.000 description 5
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
• 239000003981 vehicle Substances 0.000 description 5
• 238000005406 washing Methods 0.000 description 5
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
• LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
• 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 4
• 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 4
• 102100036849 C-C motif chemokine 24 Human genes 0.000 description 4
• 102100032367 C-C motif chemokine 5 Human genes 0.000 description 4
• 108010083647 Chemokine CCL24 Proteins 0.000 description 4
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 4
• 108091035707 Consensus sequence Proteins 0.000 description 4
• 101150074155 DHFR gene Proteins 0.000 description 4
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
• 101710146739 Enterotoxin Proteins 0.000 description 4
• 102000004190 Enzymes Human genes 0.000 description 4
• 108090000790 Enzymes Proteins 0.000 description 4
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
• 239000007995 HEPES buffer Substances 0.000 description 4
• 101000978379 Homo sapiens C-C motif chemokine 13 Proteins 0.000 description 4
• 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 description 4
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 4
• 206010061218 Inflammation Diseases 0.000 description 4
• 208000029523 Interstitial Lung disease Diseases 0.000 description 4
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
• 241000282567 Macaca fascicularis Species 0.000 description 4
• 101100495072 Macaca fascicularis CCL2 gene Proteins 0.000 description 4
• 101710091439 Major capsid protein 1 Proteins 0.000 description 4
• 101000978374 Mus musculus C-C motif chemokine 12 Proteins 0.000 description 4
• 230000004988 N-glycosylation Effects 0.000 description 4
• 241001494479 Pecora Species 0.000 description 4
• 241000288906 Primates Species 0.000 description 4
• 241000283984 Rodentia Species 0.000 description 4
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
• 206010039710 Scleroderma Diseases 0.000 description 4
• 206010040047 Sepsis Diseases 0.000 description 4
• 210000001744 T-lymphocyte Anatomy 0.000 description 4
• 239000004098 Tetracycline Substances 0.000 description 4
• 239000002253 acid Substances 0.000 description 4
• 239000004480 active ingredient Substances 0.000 description 4
• 229940100198 alkylating agent Drugs 0.000 description 4
• 239000002168 alkylating agent Substances 0.000 description 4
• 150000001412 amines Chemical class 0.000 description 4
• 230000000340 anti-metabolite Effects 0.000 description 4
• 210000000628 antibody-producing cell Anatomy 0.000 description 4
• 239000000935 antidepressant agent Substances 0.000 description 4
• 229940100197 antimetabolite Drugs 0.000 description 4
• 239000002256 antimetabolite Substances 0.000 description 4
• 239000008346 aqueous phase Substances 0.000 description 4
• 238000000149 argon plasma sintering Methods 0.000 description 4
• 230000001580 bacterial effect Effects 0.000 description 4
• 230000037396 body weight Effects 0.000 description 4
• 238000004113 cell culture Methods 0.000 description 4
• 239000003153 chemical reaction reagent Substances 0.000 description 4
• 210000000349 chromosome Anatomy 0.000 description 4
• 230000001276 controlling effect Effects 0.000 description 4
• 230000006378 damage Effects 0.000 description 4
• 238000012217 deletion Methods 0.000 description 4
• 230000037430 deletion Effects 0.000 description 4
• 238000013461 design Methods 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• 238000010790 dilution Methods 0.000 description 4
• 239000012895 dilution Substances 0.000 description 4
• 239000000539 dimer Substances 0.000 description 4
• UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 4
• POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
• 238000010828 elution Methods 0.000 description 4
• 239000000147 enterotoxin Substances 0.000 description 4
• 229940088598 enzyme Drugs 0.000 description 4
• 150000002148 esters Chemical class 0.000 description 4
• 125000005313 fatty acid group Chemical group 0.000 description 4
• 239000007789 gas Substances 0.000 description 4
• 230000036541 health Effects 0.000 description 4
• 230000009610 hypersensitivity Effects 0.000 description 4
• 239000003326 hypnotic agent Substances 0.000 description 4
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
• 230000005847 immunogenicity Effects 0.000 description 4
• 230000006872 improvement Effects 0.000 description 4
• 230000004054 inflammatory process Effects 0.000 description 4
• 238000003780 insertion Methods 0.000 description 4
• 230000037431 insertion Effects 0.000 description 4
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 4
• 238000002955 isolation Methods 0.000 description 4
• 210000004072 lung Anatomy 0.000 description 4
• 210000002540 macrophage Anatomy 0.000 description 4
• 238000013507 mapping Methods 0.000 description 4
• 230000004048 modification Effects 0.000 description 4
• 238000012986 modification Methods 0.000 description 4
• 239000003607 modifier Substances 0.000 description 4
• 229910052757 nitrogen Inorganic materials 0.000 description 4
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
• 230000009871 nonspecific binding Effects 0.000 description 4
• 239000005022 packaging material Substances 0.000 description 4
• 238000002823 phage display Methods 0.000 description 4
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
• 229920001451 polypropylene glycol Polymers 0.000 description 4
• 229920000053 polysorbate 80 Polymers 0.000 description 4
• 238000000746 purification Methods 0.000 description 4
• 238000010188 recombinant method Methods 0.000 description 4
• 230000010076 replication Effects 0.000 description 4
• 230000004044 response Effects 0.000 description 4
• 108010038379 sargramostim Proteins 0.000 description 4
• 230000035945 sensitivity Effects 0.000 description 4
• 210000003491 skin Anatomy 0.000 description 4
• 238000001228 spectrum Methods 0.000 description 4
• 238000001370 static light scattering Methods 0.000 description 4
• 150000003431 steroids Chemical class 0.000 description 4
• 238000001356 surgical procedure Methods 0.000 description 4
• 235000019364 tetracycline Nutrition 0.000 description 4
• 150000003522 tetracyclines Chemical class 0.000 description 4
• 238000011830 transgenic mouse model Methods 0.000 description 4
• 241001515965 unidentified phage Species 0.000 description 4
• UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 3
• 229930182837 (R)-adrenaline Natural products 0.000 description 3
• ZAVJTSLIGAGALR-UHFFFAOYSA-N 2-(2,2,2-trifluoroacetyl)cyclooctan-1-one Chemical compound FC(F)(F)C(=O)C1CCCCCCC1=O ZAVJTSLIGAGALR-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 3
• 201000001320 Atherosclerosis Diseases 0.000 description 3
• XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• 206010006187 Breast cancer Diseases 0.000 description 3
• 208000026310 Breast neoplasm Diseases 0.000 description 3
• 108050006947 CXC Chemokine Proteins 0.000 description 3
• 102000019388 CXC chemokine Human genes 0.000 description 3
• 229930186147 Cephalosporin Natural products 0.000 description 3
• 108010055166 Chemokine CCL5 Proteins 0.000 description 3
• 102000008186 Collagen Human genes 0.000 description 3
• 108010035532 Collagen Proteins 0.000 description 3
• 206010010774 Constipation Diseases 0.000 description 3
• 241000699802 Cricetulus griseus Species 0.000 description 3
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
• 108010036949 Cyclosporine Proteins 0.000 description 3
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
• 108010074604 Epoetin Alfa Proteins 0.000 description 3
• 102000003951 Erythropoietin Human genes 0.000 description 3
• 108090000394 Erythropoietin Proteins 0.000 description 3
• 108010008165 Etanercept Proteins 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• 102100027285 Fanconi anemia group B protein Human genes 0.000 description 3
• 108010087819 Fc receptors Proteins 0.000 description 3
• 102000009109 Fc receptors Human genes 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• 239000004471 Glycine Substances 0.000 description 3
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
• 241000238631 Hexapoda Species 0.000 description 3
• 101000713078 Homo sapiens C-C motif chemokine 24 Proteins 0.000 description 3
• 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 3
• 101000914679 Homo sapiens Fanconi anemia group B protein Proteins 0.000 description 3
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
• 239000004472 Lysine Substances 0.000 description 3
• 229940123313 MCP-1 antagonist Drugs 0.000 description 3
• 229930195725 Mannitol Natural products 0.000 description 3
• 206010027480 Metastatic malignant melanoma Diseases 0.000 description 3
• 241000283973 Oryctolagus cuniculus Species 0.000 description 3
• 208000012868 Overgrowth Diseases 0.000 description 3
• 229930182555 Penicillin Natural products 0.000 description 3
• 239000004698 Polyethylene Substances 0.000 description 3
• 108010039918 Polylysine Proteins 0.000 description 3
• 201000004681 Psoriasis Diseases 0.000 description 3
• 208000012322 Raynaud phenomenon Diseases 0.000 description 3
• 108020004511 Recombinant DNA Proteins 0.000 description 3
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 3
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
• 238000011579 SCID mouse model Methods 0.000 description 3
• 239000000150 Sympathomimetic Substances 0.000 description 3
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 239000012190 activator Substances 0.000 description 3
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 3
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 3
• 125000000217 alkyl group Chemical group 0.000 description 3
• 125000000539 amino acid group Chemical group 0.000 description 3
• 229940126575 aminoglycoside Drugs 0.000 description 3
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
• 229960000723 ampicillin Drugs 0.000 description 3
• 239000003263 anabolic agent Substances 0.000 description 3
• 239000000921 anthelmintic agent Substances 0.000 description 3
• 229940124339 anthelmintic agent Drugs 0.000 description 3
• 230000009830 antibody antigen interaction Effects 0.000 description 3
• 239000003146 anticoagulant agent Substances 0.000 description 3
• 229940127219 anticoagulant drug Drugs 0.000 description 3
• 239000002111 antiemetic agent Substances 0.000 description 3
• 229940121375 antifungal agent Drugs 0.000 description 3
• 239000003435 antirheumatic agent Substances 0.000 description 3
• 229940124584 antitussives Drugs 0.000 description 3
• 239000003443 antiviral agent Substances 0.000 description 3
• 239000002249 anxiolytic agent Substances 0.000 description 3
• 230000000949 anxiolytic effect Effects 0.000 description 3
• 229940005530 anxiolytics Drugs 0.000 description 3
• 206010003119 arrhythmia Diseases 0.000 description 3
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
• AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 3
• 229960005207 auranofin Drugs 0.000 description 3
• 229960001799 aurothioglucose Drugs 0.000 description 3
• 229960002170 azathioprine Drugs 0.000 description 3
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 3
• 229960004669 basiliximab Drugs 0.000 description 3
• 229940125388 beta agonist Drugs 0.000 description 3
• 210000004899 c-terminal region Anatomy 0.000 description 3
• 229940041011 carbapenems Drugs 0.000 description 3
• 125000004432 carbon atom Chemical group C* 0.000 description 3
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
• 229940124587 cephalosporin Drugs 0.000 description 3
• 150000001780 cephalosporins Chemical class 0.000 description 3
• 239000005482 chemotactic factor Substances 0.000 description 3
• 229960001265 ciclosporin Drugs 0.000 description 3
• 208000019425 cirrhosis of liver Diseases 0.000 description 3
• 229920001436 collagen Polymers 0.000 description 3
• 238000010276 construction Methods 0.000 description 3
• 239000003246 corticosteroid Substances 0.000 description 3
• 230000008878 coupling Effects 0.000 description 3
• 238000010168 coupling process Methods 0.000 description 3
• 238000005859 coupling reaction Methods 0.000 description 3
• 229960000265 cromoglicic acid Drugs 0.000 description 3
• IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 3
• 229930182912 cyclosporin Natural products 0.000 description 3
• 235000018417 cysteine Nutrition 0.000 description 3
• 229960002806 daclizumab Drugs 0.000 description 3
• 230000007850 degeneration Effects 0.000 description 3
• 238000009826 distribution Methods 0.000 description 3
• 229960003530 donepezil Drugs 0.000 description 3
• 108010067396 dornase alfa Proteins 0.000 description 3
• 229960005139 epinephrine Drugs 0.000 description 3
• 229960003388 epoetin alfa Drugs 0.000 description 3
• 229940105423 erythropoietin Drugs 0.000 description 3
• 239000002834 estrogen receptor modulator Substances 0.000 description 3
• 229960000403 etanercept Drugs 0.000 description 3
• 238000010265 fast atom bombardment Methods 0.000 description 3
• 239000012091 fetal bovine serum Substances 0.000 description 3
• 230000004761 fibrosis Effects 0.000 description 3
• 230000003176 fibrotic effect Effects 0.000 description 3
• 229960004177 filgrastim Drugs 0.000 description 3
• 229940124307 fluoroquinolone Drugs 0.000 description 3
• 102000037865 fusion proteins Human genes 0.000 description 3
• 108020001507 fusion proteins Proteins 0.000 description 3
• 239000000499 gel Substances 0.000 description 3
• 230000002068 genetic effect Effects 0.000 description 3
• 150000004676 glycans Chemical class 0.000 description 3
• 230000013595 glycosylation Effects 0.000 description 3
• 238000006206 glycosylation reaction Methods 0.000 description 3
• 239000000122 growth hormone Substances 0.000 description 3
• 125000001475 halogen functional group Chemical group 0.000 description 3
• 230000035876 healing Effects 0.000 description 3
• 102000043798 human CCL11 Human genes 0.000 description 3
• 102000043801 human CCL24 Human genes 0.000 description 3
• 102000051934 human CCL26 Human genes 0.000 description 3
• 229960002927 hydroxychloroquine sulfate Drugs 0.000 description 3
• 230000036039 immunity Effects 0.000 description 3
• 238000002649 immunization Methods 0.000 description 3
• 230000016784 immunoglobulin production Effects 0.000 description 3
• 229960003444 immunosuppressant agent Drugs 0.000 description 3
• 239000003018 immunosuppressive agent Substances 0.000 description 3
• 230000008676 import Effects 0.000 description 3
• 230000001939 inductive effect Effects 0.000 description 3
• 230000002458 infectious effect Effects 0.000 description 3
• 230000002757 inflammatory effect Effects 0.000 description 3
• 230000002401 inhibitory effect Effects 0.000 description 3
• 229910052500 inorganic mineral Inorganic materials 0.000 description 3
• VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 3
• 229960000681 leflunomide Drugs 0.000 description 3
• 239000003199 leukotriene receptor blocking agent Substances 0.000 description 3
• 150000002632 lipids Chemical class 0.000 description 3
• 239000003589 local anesthetic agent Substances 0.000 description 3
• 229960005015 local anesthetics Drugs 0.000 description 3
• 210000004698 lymphocyte Anatomy 0.000 description 3
• 239000008176 lyophilized powder Substances 0.000 description 3
• 239000003120 macrolide antibiotic agent Substances 0.000 description 3
• 229940041033 macrolides Drugs 0.000 description 3
• 239000000594 mannitol Substances 0.000 description 3
• 235000010355 mannitol Nutrition 0.000 description 3
• 238000001819 mass spectrum Methods 0.000 description 3
• 208000021039 metastatic melanoma Diseases 0.000 description 3
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 3
• 235000010755 mineral Nutrition 0.000 description 3
• 239000011707 mineral Substances 0.000 description 3
• 150000002772 monosaccharides Chemical class 0.000 description 3
• 201000006417 multiple sclerosis Diseases 0.000 description 3
• 238000002703 mutagenesis Methods 0.000 description 3
• 231100000350 mutagenesis Toxicity 0.000 description 3
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 3
• 229960000951 mycophenolic acid Drugs 0.000 description 3
• 230000002911 mydriatic effect Effects 0.000 description 3
• 208000010125 myocardial infarction Diseases 0.000 description 3
• 239000003158 myorelaxant agent Substances 0.000 description 3
• 239000006199 nebulizer Substances 0.000 description 3
• 230000001613 neoplastic effect Effects 0.000 description 3
• 239000000842 neuromuscular blocking agent Substances 0.000 description 3
• 238000006386 neutralization reaction Methods 0.000 description 3
• 239000000346 nonvolatile oil Substances 0.000 description 3
• 230000000414 obstructive effect Effects 0.000 description 3
• 210000001672 ovary Anatomy 0.000 description 3
• 239000001301 oxygen Substances 0.000 description 3
• 229910052760 oxygen Inorganic materials 0.000 description 3
• 238000007911 parenteral administration Methods 0.000 description 3
• 230000001717 pathogenic effect Effects 0.000 description 3
• 230000007170 pathology Effects 0.000 description 3
• 150000002960 penicillins Chemical class 0.000 description 3
• 230000002093 peripheral effect Effects 0.000 description 3
• 238000001050 pharmacotherapy Methods 0.000 description 3
• 229960005190 phenylalanine Drugs 0.000 description 3
• 239000008363 phosphate buffer Substances 0.000 description 3
• 229920003023 plastic Polymers 0.000 description 3
• 239000004033 plastic Substances 0.000 description 3
• 229920000656 polylysine Polymers 0.000 description 3
• 238000003752 polymerase chain reaction Methods 0.000 description 3
• 239000005017 polysaccharide Substances 0.000 description 3
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
• 210000001236 prokaryotic cell Anatomy 0.000 description 3
• 239000012217 radiopharmaceutical Substances 0.000 description 3
• 229940121896 radiopharmaceutical Drugs 0.000 description 3
• 230000002799 radiopharmaceutical effect Effects 0.000 description 3
• 238000003259 recombinant expression Methods 0.000 description 3
• 238000011084 recovery Methods 0.000 description 3
• 210000002345 respiratory system Anatomy 0.000 description 3
• 208000037803 restenosis Diseases 0.000 description 3
• 206010039073 rheumatoid arthritis Diseases 0.000 description 3
• 229960002530 sargramostim Drugs 0.000 description 3
• 230000003248 secreting effect Effects 0.000 description 3
• 239000000932 sedative agent Substances 0.000 description 3
• 229940125723 sedative agent Drugs 0.000 description 3
• 150000003384 small molecules Chemical class 0.000 description 3
• AGHLUVOCTHWMJV-UHFFFAOYSA-J sodium;gold(3+);2-sulfanylbutanedioate Chemical compound [Na+].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O AGHLUVOCTHWMJV-UHFFFAOYSA-J 0.000 description 3
• 125000006850 spacer group Chemical group 0.000 description 3
• 230000009870 specific binding Effects 0.000 description 3
• 238000001694 spray drying Methods 0.000 description 3
• 239000000021 stimulant Substances 0.000 description 3
• 150000005846 sugar alcohols Chemical class 0.000 description 3
• 150000008163 sugars Chemical class 0.000 description 3
• 229940124530 sulfonamide Drugs 0.000 description 3
• 150000003456 sulfonamides Chemical class 0.000 description 3
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
• 230000001975 sympathomimetic effect Effects 0.000 description 3
• 229940064707 sympathomimetics Drugs 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 3
• 229960001685 tacrine Drugs 0.000 description 3
• TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 3
• 210000001685 thyroid gland Anatomy 0.000 description 3
• 230000014616 translation Effects 0.000 description 3
• 102000003298 tumor necrosis factor receptor Human genes 0.000 description 3
• 241000701447 unidentified baculovirus Species 0.000 description 3
• 238000002255 vaccination Methods 0.000 description 3
• 229940088594 vitamin Drugs 0.000 description 3
• 229930003231 vitamin Natural products 0.000 description 3
• 235000013343 vitamin Nutrition 0.000 description 3
• 239000011782 vitamin Substances 0.000 description 3
• 230000003442 weekly effect Effects 0.000 description 3
• HDTRYLNUVZCQOY-UHFFFAOYSA-N &alpha;-D-glucopyranosyl-&alpha;-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
• CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
• PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 description 2
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
• 102000009027 Albumins Human genes 0.000 description 2
• 108010088751 Albumins Proteins 0.000 description 2
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
• 208000024827 Alzheimer disease Diseases 0.000 description 2
• 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 2
• 108020005544 Antisense RNA Proteins 0.000 description 2
• 239000004475 Arginine Substances 0.000 description 2
• 206010003210 Arteriosclerosis Diseases 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical class OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 206010003591 Ataxia Diseases 0.000 description 2
• 208000012657 Atopic disease Diseases 0.000 description 2
• 102100022718 Atypical chemokine receptor 2 Human genes 0.000 description 2
• 208000035143 Bacterial infection Diseases 0.000 description 2
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 2
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 2
• 208000006386 Bone Resorption Diseases 0.000 description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
• 206010006448 Bronchiolitis Diseases 0.000 description 2
• 108700013048 CCL2 Proteins 0.000 description 2
• 102000004499 CCR3 Receptors Human genes 0.000 description 2
• 108010017316 CCR3 Receptors Proteins 0.000 description 2
• 206010006895 Cachexia Diseases 0.000 description 2
• 101710132601 Capsid protein Proteins 0.000 description 2
• 208000031229 Cardiomyopathies Diseases 0.000 description 2
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
• 102000014914 Carrier Proteins Human genes 0.000 description 2
• 208000015879 Cerebellar disease Diseases 0.000 description 2
• 102000009410 Chemokine receptor Human genes 0.000 description 2
• 108050000299 Chemokine receptor Proteins 0.000 description 2
• 206010008631 Cholera Diseases 0.000 description 2
• 241000193403 Clostridium Species 0.000 description 2
• 208000035473 Communicable disease Diseases 0.000 description 2
• 201000003883 Cystic fibrosis Diseases 0.000 description 2
• RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
• 201000004624 Dermatitis Diseases 0.000 description 2
• 206010012442 Dermatitis contact Diseases 0.000 description 2
• 206010012689 Diabetic retinopathy Diseases 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
• 108700007698 Genetic Terminator Regions Proteins 0.000 description 2
• 206010018364 Glomerulonephritis Diseases 0.000 description 2
• INGJLBQKTRJLFO-UKJIMTQDSA-N Glu-Ile-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(O)=O INGJLBQKTRJLFO-UKJIMTQDSA-N 0.000 description 2
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
• 108010051696 Growth Hormone Proteins 0.000 description 2
• 102000018997 Growth Hormone Human genes 0.000 description 2
• 206010019280 Heart failures Diseases 0.000 description 2
• 208000032843 Hemorrhage Diseases 0.000 description 2
• 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 description 2
• 101000777558 Homo sapiens C-C chemokine receptor type 10 Proteins 0.000 description 2
• 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 2
• 108090000144 Human Proteins Proteins 0.000 description 2
• 206010020772 Hypertension Diseases 0.000 description 2
• 206010020880 Hypertrophy Diseases 0.000 description 2
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
• 108010002350 Interleukin-2 Proteins 0.000 description 2
• 102000000588 Interleukin-2 Human genes 0.000 description 2
• 108091092195 Intron Proteins 0.000 description 2
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
• 208000019693 Lung disease Diseases 0.000 description 2
• 201000009906 Meningitis Diseases 0.000 description 2
• 241000699660 Mus musculus Species 0.000 description 2
• 101000897464 Mus musculus C-C motif chemokine 2 Proteins 0.000 description 2
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
• 229930193140 Neomycin Natural products 0.000 description 2
• 206010029164 Nephrotic syndrome Diseases 0.000 description 2
• 244000061176 Nicotiana tabacum Species 0.000 description 2
• 108091034117 Oligonucleotide Proteins 0.000 description 2
• 108700026244 Open Reading Frames Proteins 0.000 description 2
• 208000001132 Osteoporosis Diseases 0.000 description 2
• 229930012538 Paclitaxel Natural products 0.000 description 2
• 108010067902 Peptide Library Proteins 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
• 229920000954 Polyglycolide Polymers 0.000 description 2
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 2
• MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 2
• 208000003782 Raynaud disease Diseases 0.000 description 2
• 206010063837 Reperfusion injury Diseases 0.000 description 2
• 206010039085 Rhinitis allergic Diseases 0.000 description 2
• 241000607142 Salmonella Species 0.000 description 2
• 206010040070 Septic Shock Diseases 0.000 description 2
• 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 description 2
• 241000191967 Staphylococcus aureus Species 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
• 108010022394 Threonine synthase Proteins 0.000 description 2
• 206010044248 Toxic shock syndrome Diseases 0.000 description 2
• 231100000650 Toxic shock syndrome Toxicity 0.000 description 2
• 101710101607 Toxic shock syndrome toxin-1 Proteins 0.000 description 2
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
• MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
• 206010047115 Vasculitis Diseases 0.000 description 2
• 241000607598 Vibrio Species 0.000 description 2
• TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
• 238000009825 accumulation Methods 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 208000018254 acute transverse myelitis Diseases 0.000 description 2
• 238000001042 affinity chromatography Methods 0.000 description 2
• 230000000172 allergic effect Effects 0.000 description 2
• 201000010105 allergic rhinitis Diseases 0.000 description 2
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
• 125000003277 amino group Chemical group 0.000 description 2
• 229940070021 anabolic steroids Drugs 0.000 description 2
• 230000000202 analgesic effect Effects 0.000 description 2
• 229940035676 analgesics Drugs 0.000 description 2
• 238000000540 analysis of variance Methods 0.000 description 2
• 229940035674 anesthetics Drugs 0.000 description 2
• 239000002333 angiotensin II receptor antagonist Substances 0.000 description 2
• 229940125364 angiotensin receptor blocker Drugs 0.000 description 2
• 230000000954 anitussive effect Effects 0.000 description 2
• 239000000730 antalgic agent Substances 0.000 description 2
• 230000001142 anti-diarrhea Effects 0.000 description 2
• 230000003474 anti-emetic effect Effects 0.000 description 2
• 239000002260 anti-inflammatory agent Substances 0.000 description 2
• 229940121363 anti-inflammatory agent Drugs 0.000 description 2
• 229940088710 antibiotic agent Drugs 0.000 description 2
• 229940005513 antidepressants Drugs 0.000 description 2
• 239000003793 antidiarrheal agent Substances 0.000 description 2
• 239000003429 antifungal agent Substances 0.000 description 2
• 229960005475 antiinfective agent Drugs 0.000 description 2
• 239000000228 antimanic agent Substances 0.000 description 2
• 239000004599 antimicrobial Substances 0.000 description 2
• 229940041181 antineoplastic drug Drugs 0.000 description 2
• 239000003963 antioxidant agent Substances 0.000 description 2
• 235000006708 antioxidants Nutrition 0.000 description 2
• 239000000164 antipsychotic agent Substances 0.000 description 2
• 229940005529 antipsychotics Drugs 0.000 description 2
• 239000003434 antitussive agent Substances 0.000 description 2
• 239000003699 antiulcer agent Substances 0.000 description 2
• YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
• 230000006793 arrhythmia Effects 0.000 description 2
• 208000011775 arteriosclerosis disease Diseases 0.000 description 2
• 235000003704 aspartic acid Nutrition 0.000 description 2
• 230000003143 atherosclerotic effect Effects 0.000 description 2
• 208000010668 atopic eczema Diseases 0.000 description 2
• 208000022362 bacterial infectious disease Diseases 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
• 238000013357 binding ELISA Methods 0.000 description 2
• 239000012148 binding buffer Substances 0.000 description 2
• 108091008324 binding proteins Proteins 0.000 description 2
• 230000000975 bioactive effect Effects 0.000 description 2
• 230000008033 biological extinction Effects 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 229960000074 biopharmaceutical Drugs 0.000 description 2
• 238000007413 biotinylation Methods 0.000 description 2
• 230000006287 biotinylation Effects 0.000 description 2
• 229920001400 block copolymer Polymers 0.000 description 2
• 239000010836 blood and blood product Substances 0.000 description 2
• 229940125691 blood product Drugs 0.000 description 2
• 210000000988 bone and bone Anatomy 0.000 description 2
• 230000024279 bone resorption Effects 0.000 description 2
• 239000006172 buffering agent Substances 0.000 description 2
• 229960005069 calcium Drugs 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 229910002091 carbon monoxide Inorganic materials 0.000 description 2
• 229960005243 carmustine Drugs 0.000 description 2
• 239000005018 casein Substances 0.000 description 2
• BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
• 235000021240 caseins Nutrition 0.000 description 2
• 238000000423 cell based assay Methods 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 239000002738 chelating agent Substances 0.000 description 2
• 125000003636 chemical group Chemical group 0.000 description 2
• 239000002975 chemoattractant Substances 0.000 description 2
• 210000000038 chest Anatomy 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 230000001886 ciliary effect Effects 0.000 description 2
• 230000007882 cirrhosis Effects 0.000 description 2
• 238000011260 co-administration Methods 0.000 description 2
• 239000011248 coating agent Substances 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 238000002648 combination therapy Methods 0.000 description 2
• 230000002860 competitive effect Effects 0.000 description 2
• 239000003184 complementary RNA Substances 0.000 description 2
• 210000002808 connective tissue Anatomy 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 229960001334 corticosteroids Drugs 0.000 description 2
• 238000012258 culturing Methods 0.000 description 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
• 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 2
• 238000000586 desensitisation Methods 0.000 description 2
• 229910052805 deuterium Inorganic materials 0.000 description 2
• 150000001991 dicarboxylic acids Chemical class 0.000 description 2
• 102000004419 dihydrofolate reductase Human genes 0.000 description 2
• 150000002016 disaccharides Chemical class 0.000 description 2
• 239000006185 dispersion Substances 0.000 description 2
• 229960000533 dornase alfa Drugs 0.000 description 2
• 230000007783 downstream signaling Effects 0.000 description 2
• 238000004520 electroporation Methods 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 230000002124 endocrine Effects 0.000 description 2
• 239000002158 endotoxin Substances 0.000 description 2
• 238000001704 evaporation Methods 0.000 description 2
• 239000013613 expression plasmid Substances 0.000 description 2
• 238000004108 freeze drying Methods 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 239000003193 general anesthetic agent Substances 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 235000013922 glutamic acid Nutrition 0.000 description 2
• 239000004220 glutamic acid Substances 0.000 description 2
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
• 102000035122 glycosylated proteins Human genes 0.000 description 2
• 108091005608 glycosylated proteins Proteins 0.000 description 2
• 239000001963 growth medium Substances 0.000 description 2
• 208000006454 hepatitis Diseases 0.000 description 2
• 231100000283 hepatitis Toxicity 0.000 description 2
• 238000004128 high performance liquid chromatography Methods 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• 230000013632 homeostatic process Effects 0.000 description 2
• 239000003667 hormone antagonist Substances 0.000 description 2
• 229910052739 hydrogen Inorganic materials 0.000 description 2
• VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 208000026278 immune system disease Diseases 0.000 description 2
• 230000001861 immunosuppressant effect Effects 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 229960000598 infliximab Drugs 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• 230000010354 integration Effects 0.000 description 2
• 229960000310 isoleucine Drugs 0.000 description 2
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
• BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
• 239000007951 isotonicity adjuster Substances 0.000 description 2
• 238000005304 joining Methods 0.000 description 2
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
• 210000003292 kidney cell Anatomy 0.000 description 2
• 239000004310 lactic acid Substances 0.000 description 2
• 230000003902 lesion Effects 0.000 description 2
• 208000032839 leukemia Diseases 0.000 description 2
• 210000000265 leukocyte Anatomy 0.000 description 2
• 108020001756 ligand binding domains Proteins 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 108010019677 lymphotactin Proteins 0.000 description 2
• RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
• 230000010534 mechanism of action Effects 0.000 description 2
• 229940127554 medical product Drugs 0.000 description 2
• 201000001441 melanoma Diseases 0.000 description 2
• HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
• 229940071648 metered dose inhaler Drugs 0.000 description 2
• 229930182817 methionine Natural products 0.000 description 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
• 230000000394 mitotic effect Effects 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 238000010369 molecular cloning Methods 0.000 description 2
• 210000003205 muscle Anatomy 0.000 description 2
• 239000013642 negative control Substances 0.000 description 2
• 229960004927 neomycin Drugs 0.000 description 2
• 201000008383 nephritis Diseases 0.000 description 2
• 229940029345 neupogen Drugs 0.000 description 2
• 239000002773 nucleotide Substances 0.000 description 2
• 125000003729 nucleotide group Chemical group 0.000 description 2
• 230000000474 nursing effect Effects 0.000 description 2
• QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 2
• BNJOQKFENDDGSC-UHFFFAOYSA-N octadecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCCCCCC(O)=O BNJOQKFENDDGSC-UHFFFAOYSA-N 0.000 description 2
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
• TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
• 229920001542 oligosaccharide Polymers 0.000 description 2
• 150000002482 oligosaccharides Chemical class 0.000 description 2
• 230000003287 optical effect Effects 0.000 description 2
• 125000000962 organic group Chemical group 0.000 description 2
• 230000003204 osmotic effect Effects 0.000 description 2
• 201000008482 osteoarthritis Diseases 0.000 description 2
• IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
• 229960001592 paclitaxel Drugs 0.000 description 2
• 208000008443 pancreatic carcinoma Diseases 0.000 description 2
• 210000005259 peripheral blood Anatomy 0.000 description 2
• 239000011886 peripheral blood Substances 0.000 description 2
• 229940124531 pharmaceutical excipient Drugs 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
• 239000013600 plasmid vector Substances 0.000 description 2
• 229920000747 poly(lactic acid) Polymers 0.000 description 2
• 229920001610 polycaprolactone Polymers 0.000 description 2
• 239000004633 polyglycolic acid Substances 0.000 description 2
• 239000004626 polylactic acid Substances 0.000 description 2
• 238000006116 polymerization reaction Methods 0.000 description 2
• 229920000136 polysorbate Polymers 0.000 description 2
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
• 239000002244 precipitate Substances 0.000 description 2
• 238000001556 precipitation Methods 0.000 description 2
• 239000003380 propellant Substances 0.000 description 2
• 238000003908 quality control method Methods 0.000 description 2
• MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
• 230000008707 rearrangement Effects 0.000 description 2
• 238000001525 receptor binding assay Methods 0.000 description 2
• 230000006798 recombination Effects 0.000 description 2
• 238000005215 recombination Methods 0.000 description 2
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
• 230000029058 respiratory gaseous exchange Effects 0.000 description 2
• 108091008146 restriction endonucleases Proteins 0.000 description 2
• 238000004007 reversed phase HPLC Methods 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 201000000306 sarcoidosis Diseases 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 239000006152 selective media Substances 0.000 description 2
• 238000002864 sequence alignment Methods 0.000 description 2
• 208000017520 skin disease Diseases 0.000 description 2
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
• 238000001179 sorption measurement Methods 0.000 description 2
• 210000000952 spleen Anatomy 0.000 description 2
• 239000007921 spray Substances 0.000 description 2
• 206010041823 squamous cell carcinoma Diseases 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 229910052717 sulfur Inorganic materials 0.000 description 2
• 238000010189 synthetic method Methods 0.000 description 2
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
• 229960002180 tetracycline Drugs 0.000 description 2
• 229930101283 tetracycline Natural products 0.000 description 2
• 229940040944 tetracyclines Drugs 0.000 description 2
• HQHCYKULIHKCEB-UHFFFAOYSA-N tetradecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCC(O)=O HQHCYKULIHKCEB-UHFFFAOYSA-N 0.000 description 2
• 230000002103 transcriptional effect Effects 0.000 description 2
• 230000010474 transient expression Effects 0.000 description 2
• 238000013519 translation Methods 0.000 description 2
• 238000002054 transplantation Methods 0.000 description 2
• 208000009174 transverse myelitis Diseases 0.000 description 2
• 210000004881 tumor cell Anatomy 0.000 description 2
• 241001430294 unidentified retrovirus Species 0.000 description 2
• 239000004474 valine Substances 0.000 description 2
• 150000003722 vitamin derivatives Chemical class 0.000 description 2
• 230000029663 wound healing Effects 0.000 description 2
• 229940075420 xanthine Drugs 0.000 description 2
• 239000000811 xylitol Substances 0.000 description 2
• 235000010447 xylitol Nutrition 0.000 description 2
• HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
• 229960002675 xylitol Drugs 0.000 description 2
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 1
• VAIZVCMDJPBJCM-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-one;trihydrate Chemical compound O.O.O.FC(F)(F)C(=O)C(F)(F)F.FC(F)(F)C(=O)C(F)(F)F VAIZVCMDJPBJCM-UHFFFAOYSA-N 0.000 description 1
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
• VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
• 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
• OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
• PMUNIMVZCACZBB-UHFFFAOYSA-N 2-hydroxyethylazanium;chloride Chemical compound Cl.NCCO PMUNIMVZCACZBB-UHFFFAOYSA-N 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• 108050001326 26S Proteasome regulatory subunit 6A Proteins 0.000 description 1
• 102100029510 26S proteasome regulatory subunit 6A Human genes 0.000 description 1
• 108020005065 3' Flanking Region Proteins 0.000 description 1
• SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
• 101710162847 8.6 kDa protein Proteins 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 241000251468 Actinopterygii Species 0.000 description 1
• 102000007469 Actins Human genes 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 208000009304 Acute Kidney Injury Diseases 0.000 description 1
• 206010000830 Acute leukaemia Diseases 0.000 description 1
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
• 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
• 208000026872 Addison Disease Diseases 0.000 description 1
• 241000607534 Aeromonas Species 0.000 description 1
• 241000607516 Aeromonas caviae Species 0.000 description 1
• 108700018394 Aeromonas cytolytic enterotoxin Proteins 0.000 description 1
• 241000607528 Aeromonas hydrophila Species 0.000 description 1
• 241000607522 Aeromonas sobria Species 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 1
• 208000007848 Alcoholism Diseases 0.000 description 1
• 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
• 201000004384 Alopecia Diseases 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 206010001881 Alveolar proteinosis Diseases 0.000 description 1
• 206010001889 Alveolitis Diseases 0.000 description 1
• 206010002198 Anaphylactic reaction Diseases 0.000 description 1
• 206010002383 Angina Pectoris Diseases 0.000 description 1
• 206010002388 Angina unstable Diseases 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 108090000669 Annexin A4 Proteins 0.000 description 1
• 102100034612 Annexin A4 Human genes 0.000 description 1
• 108010032595 Antibody Binding Sites Proteins 0.000 description 1
• 239000001904 Arabinogalactan Substances 0.000 description 1
• 229920000189 Arabinogalactan Polymers 0.000 description 1
• 206010003226 Arteriovenous fistula Diseases 0.000 description 1
• 206010053555 Arthritis bacterial Diseases 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 108010011485 Aspartame Proteins 0.000 description 1
• 206010003497 Asphyxia Diseases 0.000 description 1
• 206010003598 Atelectasis Diseases 0.000 description 1
• 206010003658 Atrial Fibrillation Diseases 0.000 description 1
• 206010003662 Atrial flutter Diseases 0.000 description 1
• 206010003671 Atrioventricular Block Diseases 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 208000037157 Azotemia Diseases 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• 231100000699 Bacterial toxin Toxicity 0.000 description 1
• 208000023328 Basedow disease Diseases 0.000 description 1
• 235000021357 Behenic acid Nutrition 0.000 description 1
• KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
• 208000019838 Blood disease Diseases 0.000 description 1
• 206010006002 Bone pain Diseases 0.000 description 1
• 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
• 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
• 102000004500 CCR1 Receptors Human genes 0.000 description 1
• 108010017319 CCR1 Receptors Proteins 0.000 description 1
• 240000001432 Calendula officinalis Species 0.000 description 1
• 235000005881 Calendula officinalis Nutrition 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 206010007559 Cardiac failure congestive Diseases 0.000 description 1
• 208000000135 Cardiovascular Syphilis Diseases 0.000 description 1
• 101150075117 Ccl12 gene Proteins 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 108020004998 Chloroplast DNA Proteins 0.000 description 1
• 108020005133 Chloroplast RNA Proteins 0.000 description 1
• 206010008748 Chorea Diseases 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• 206010008909 Chronic Hepatitis Diseases 0.000 description 1
• 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
• 241000193155 Clostridium botulinum Species 0.000 description 1
• 241000193468 Clostridium perfringens Species 0.000 description 1
• 101710094648 Coat protein Proteins 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• 108700010070 Codon Usage Proteins 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
• 206010010741 Conjunctivitis Diseases 0.000 description 1
• 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
• 208000034656 Contusions Diseases 0.000 description 1
• 241000557626 Corvus corax Species 0.000 description 1
• 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 241000195493 Cryptophyta Species 0.000 description 1
• 229920001651 Cyanoacrylate Polymers 0.000 description 1
• 206010011703 Cyanosis Diseases 0.000 description 1
• 229920000858 Cyclodextrin Polymers 0.000 description 1
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
• 101710112752 Cytotoxin Proteins 0.000 description 1
• GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Chemical class OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
• QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
• 230000007023 DNA restriction-modification system Effects 0.000 description 1
• 238000001712 DNA sequencing Methods 0.000 description 1
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
• 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
• 206010012289 Dementia Diseases 0.000 description 1
• 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
• 208000016192 Demyelinating disease Diseases 0.000 description 1
• 206010012310 Dengue fever Diseases 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
• 108090000204 Dipeptidase 1 Proteins 0.000 description 1
• 208000002251 Dissecting Aneurysm Diseases 0.000 description 1
• 102000015554 Dopamine receptor Human genes 0.000 description 1
• 108050004812 Dopamine receptor Proteins 0.000 description 1
• 201000010374 Down Syndrome Diseases 0.000 description 1
• 241001269524 Dura Species 0.000 description 1
• 206010014612 Encephalitis viral Diseases 0.000 description 1
• 201000009273 Endometriosis Diseases 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 241001646719 Escherichia coli O157:H7 Species 0.000 description 1
• 241000206602 Eukaryota Species 0.000 description 1
• 206010073306 Exposure to radiation Diseases 0.000 description 1
• 208000027776 Extrapyramidal disease Diseases 0.000 description 1
• 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 1
• 208000035366 Familial hemophagocytic lymphohistiocytosis Diseases 0.000 description 1
• 208000002633 Febrile Neutropenia Diseases 0.000 description 1
• 229920001917 Ficoll Polymers 0.000 description 1
• 206010016717 Fistula Diseases 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• 208000024412 Friedreich ataxia Diseases 0.000 description 1
• 229930091371 Fructose Natural products 0.000 description 1
• 239000005715 Fructose Substances 0.000 description 1
• RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
• 206010017533 Fungal infection Diseases 0.000 description 1
• 206010058872 Fungal sepsis Diseases 0.000 description 1
• 108091006027 G proteins Proteins 0.000 description 1
• 101150074355 GS gene Proteins 0.000 description 1
• 102000030782 GTP binding Human genes 0.000 description 1
• 108091000058 GTP-Binding Proteins 0.000 description 1
• 201000000628 Gas Gangrene Diseases 0.000 description 1
• 206010017914 Gastroenteritis salmonella Diseases 0.000 description 1
• 208000032612 Glial tumor Diseases 0.000 description 1
• 206010018338 Glioma Diseases 0.000 description 1
• ZFBBMCKQSNJZSN-AUTRQRHGSA-N Gln-Val-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZFBBMCKQSNJZSN-AUTRQRHGSA-N 0.000 description 1
• 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
• 208000024869 Goodpasture syndrome Diseases 0.000 description 1
• BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
• 108010069236 Goserelin Proteins 0.000 description 1
• 208000009329 Graft vs Host Disease Diseases 0.000 description 1
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 241000288105 Grus Species 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 208000037357 HIV infectious disease Diseases 0.000 description 1
• 208000031071 Hamman-Rich Syndrome Diseases 0.000 description 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
• 206010019315 Heart transplant rejection Diseases 0.000 description 1
• 101710121697 Heat-stable enterotoxin Proteins 0.000 description 1
• 241000589989 Helicobacter Species 0.000 description 1
• 208000018565 Hemochromatosis Diseases 0.000 description 1
• 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 1
• 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 description 1
• 208000014669 Hemophagocytic syndrome associated with an infection Diseases 0.000 description 1
• 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
• 206010019755 Hepatitis chronic active Diseases 0.000 description 1
• 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
• 208000002291 Histiocytic Sarcoma Diseases 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
• 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
• 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 description 1
• 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 description 1
• 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 description 1
• 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 description 1
• 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 description 1
• 101000635804 Homo sapiens Tissue factor Proteins 0.000 description 1
• 108010000521 Human Growth Hormone Proteins 0.000 description 1
• 102000002265 Human Growth Hormone Human genes 0.000 description 1
• 239000000854 Human Growth Hormone Substances 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• 241000701109 Human adenovirus 2 Species 0.000 description 1
• 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
• 208000023105 Huntington disease Diseases 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• 208000037147 Hypercalcaemia Diseases 0.000 description 1
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
• 208000009995 Idiopathic pulmonary hemosiderosis Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 108700002232 Immediate-Early Genes Proteins 0.000 description 1
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
• 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
• 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
• 102100022964 Immunoglobulin kappa variable 3-20 Human genes 0.000 description 1
• 208000004575 Infectious Arthritis Diseases 0.000 description 1
• 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 206010022489 Insulin Resistance Diseases 0.000 description 1
• 108010078049 Interferon alpha-2 Proteins 0.000 description 1
• 102100039350 Interferon alpha-7 Human genes 0.000 description 1
• 108010047761 Interferon-alpha Proteins 0.000 description 1
• 102000006992 Interferon-alpha Human genes 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 206010072877 Intestinal fibrosis Diseases 0.000 description 1
• 206010022941 Iridocyclitis Diseases 0.000 description 1
• 208000032382 Ischaemic stroke Diseases 0.000 description 1
• 208000035901 Ischaemic ulcer Diseases 0.000 description 1
• UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
• 208000003456 Juvenile Arthritis Diseases 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• 206010023439 Kidney transplant rejection Diseases 0.000 description 1
• 241000588748 Klebsiella Species 0.000 description 1
• 208000006264 Korsakoff syndrome Diseases 0.000 description 1
• LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• 208000034693 Laceration Diseases 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 1
• 239000005639 Lauric acid Substances 0.000 description 1
• 108090001090 Lectins Proteins 0.000 description 1
• 102000004856 Lectins Human genes 0.000 description 1
• 241000589248 Legionella Species 0.000 description 1
• 208000007764 Legionnaires' Disease Diseases 0.000 description 1
• 208000004554 Leishmaniasis Diseases 0.000 description 1
• 241000270322 Lepidosauria Species 0.000 description 1
• 206010024229 Leprosy Diseases 0.000 description 1
• 108010000817 Leuprolide Proteins 0.000 description 1
• 208000009829 Lewy Body Disease Diseases 0.000 description 1
• 206010024558 Lip oedema Diseases 0.000 description 1
• 208000007021 Lipedema Diseases 0.000 description 1
• 206010024715 Liver transplant rejection Diseases 0.000 description 1
• 206010051604 Lung transplant rejection Diseases 0.000 description 1
• 208000005777 Lupus Nephritis Diseases 0.000 description 1
• 208000016604 Lyme disease Diseases 0.000 description 1
• 206010025282 Lymphoedema Diseases 0.000 description 1
• 101710125418 Major capsid protein Proteins 0.000 description 1
• 101710091437 Major capsid protein 2 Proteins 0.000 description 1
• PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
• 229920002774 Maltodextrin Polymers 0.000 description 1
• 239000005913 Maltodextrin Substances 0.000 description 1
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• 208000019695 Migraine disease Diseases 0.000 description 1
• 108020005196 Mitochondrial DNA Proteins 0.000 description 1
• 229940121849 Mitotic inhibitor Drugs 0.000 description 1
• 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
• 102100035971 Molybdopterin molybdenumtransferase Human genes 0.000 description 1
• 101710119577 Molybdopterin molybdenumtransferase Proteins 0.000 description 1
• 206010060880 Monoclonal gammopathy Diseases 0.000 description 1
• 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
• 108090000143 Mouse Proteins Proteins 0.000 description 1
• 208000016285 Movement disease Diseases 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 241000714177 Murine leukemia virus Species 0.000 description 1
• 101100382870 Mus musculus Ccl12 gene Proteins 0.000 description 1
• 101100495074 Mus musculus Ccl2 gene Proteins 0.000 description 1
• 101100278853 Mus musculus Dhfr gene Proteins 0.000 description 1
• 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
• 241000204031 Mycoplasma Species 0.000 description 1
• 208000031888 Mycoses Diseases 0.000 description 1
• 208000003926 Myelitis Diseases 0.000 description 1
• 201000002481 Myositis Diseases 0.000 description 1
• 235000021360 Myristic acid Nutrition 0.000 description 1
• KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
• 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
• 238000005481 NMR spectroscopy Methods 0.000 description 1
• 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
• 229920002274 Nalgene Polymers 0.000 description 1
• 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
• 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
• 208000009905 Neurofibromatoses Diseases 0.000 description 1
• 102000008763 Neurofilament Proteins Human genes 0.000 description 1
• 108010088373 Neurofilament Proteins Proteins 0.000 description 1
• 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
• 208000009893 Nonpenetrating Wounds Diseases 0.000 description 1
• 101710141454 Nucleoprotein Proteins 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
• 208000003435 Optic Neuritis Diseases 0.000 description 1
• 206010053869 POEMS syndrome Diseases 0.000 description 1
• 206010049169 Pancreas transplant rejection Diseases 0.000 description 1
• 206010033645 Pancreatitis Diseases 0.000 description 1
• 206010033647 Pancreatitis acute Diseases 0.000 description 1
• 108700020797 Parathyroid Hormone-Related Proteins 0.000 description 1
• 102000043299 Parathyroid hormone-related Human genes 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 206010058674 Pelvic Infection Diseases 0.000 description 1
• 241000721454 Pemphigus Species 0.000 description 1
• 208000009344 Penetrating Wounds Diseases 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 208000025584 Pericardial disease Diseases 0.000 description 1
• 208000018262 Peripheral vascular disease Diseases 0.000 description 1
• 208000031845 Pernicious anaemia Diseases 0.000 description 1
• 206010057249 Phagocytosis Diseases 0.000 description 1
• 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
• 241000606999 Plesiomonas shigelloides Species 0.000 description 1
• 208000005384 Pneumocystis Pneumonia Diseases 0.000 description 1
• 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 1
• 239000004952 Polyamide Substances 0.000 description 1
• 206010036105 Polyneuropathy Diseases 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• 229920001219 Polysorbate 40 Polymers 0.000 description 1
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• 101710083689 Probable capsid protein Proteins 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
• 102000007066 Prostate-Specific Antigen Human genes 0.000 description 1
• 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 208000032225 Proximal spinal muscular atrophy type 1 Diseases 0.000 description 1
• 208000033526 Proximal spinal muscular atrophy type 3 Diseases 0.000 description 1
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
• 208000028017 Psychotic disease Diseases 0.000 description 1
• 208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
• 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
• 238000002123 RNA extraction Methods 0.000 description 1
• 239000012979 RPMI medium Substances 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 101100409194 Rattus norvegicus Ppargc1b gene Proteins 0.000 description 1
• 208000005587 Refsum Disease Diseases 0.000 description 1
• 208000006265 Renal cell carcinoma Diseases 0.000 description 1
• 208000033626 Renal failure acute Diseases 0.000 description 1
• 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
• 206010039094 Rhinitis perennial Diseases 0.000 description 1
• 241000282806 Rhinoceros Species 0.000 description 1
• 108010039491 Ricin Proteins 0.000 description 1
• 241000714474 Rous sarcoma virus Species 0.000 description 1
• 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 206010039509 Scab Diseases 0.000 description 1
• 206010039966 Senile dementia Diseases 0.000 description 1
• 238000012300 Sequence Analysis Methods 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 208000009714 Severe Dengue Diseases 0.000 description 1
• 108010079723 Shiga Toxin Proteins 0.000 description 1
• 241000607766 Shigella boydii Species 0.000 description 1
• 241000607764 Shigella dysenteriae Species 0.000 description 1
• 241000607762 Shigella flexneri Species 0.000 description 1
• 241000607760 Shigella sonnei Species 0.000 description 1
• 206010050207 Skin fibrosis Diseases 0.000 description 1
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
• 244000061456 Solanum tuberosum Species 0.000 description 1
• 235000002595 Solanum tuberosum Nutrition 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 208000007107 Stomach Ulcer Diseases 0.000 description 1
• 241000194017 Streptococcus Species 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
• 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 101001086866 Sus scrofa Pulmonary surfactant-associated protein B Proteins 0.000 description 1
• 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
• 208000004732 Systemic Vasculitis Diseases 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 208000001871 Tachycardia Diseases 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 206010043189 Telangiectasia Diseases 0.000 description 1
• BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
• 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
• 108091036066 Three prime untranslated region Proteins 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 208000007814 Unstable Angina Diseases 0.000 description 1
• 208000024780 Urticaria Diseases 0.000 description 1
• 206010046851 Uveitis Diseases 0.000 description 1
• 101150117115 V gene Proteins 0.000 description 1
• 206010046996 Varicose vein Diseases 0.000 description 1
• 206010047249 Venous thrombosis Diseases 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 108020000999 Viral RNA Proteins 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 206010047642 Vitiligo Diseases 0.000 description 1
• 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 description 1
• 239000005862 Whey Substances 0.000 description 1
• 102000007544 Whey Proteins Human genes 0.000 description 1
• 108010046377 Whey Proteins Proteins 0.000 description 1
• 208000018839 Wilson disease Diseases 0.000 description 1
• 241000607734 Yersinia <bacteria> Species 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• 210000001015 abdomen Anatomy 0.000 description 1
• 208000004622 abetalipoproteinemia Diseases 0.000 description 1
• 238000002679 ablation Methods 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 239000008351 acetate buffer Substances 0.000 description 1
• 201000004073 acute interstitial pneumonia Diseases 0.000 description 1
• 201000011040 acute kidney failure Diseases 0.000 description 1
• 201000003229 acute pancreatitis Diseases 0.000 description 1
• 208000012998 acute renal failure Diseases 0.000 description 1
• 208000009956 adenocarcinoma Diseases 0.000 description 1
• 230000001464 adherent effect Effects 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 208000030597 adult Refsum disease Diseases 0.000 description 1
• 229960003227 afelimomab Drugs 0.000 description 1
• 238000001261 affinity purification Methods 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 235000010419 agar Nutrition 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
• 238000012867 alanine scanning Methods 0.000 description 1
• 150000001295 alanines Chemical group 0.000 description 1
• NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
• 208000002353 alcoholic hepatitis Diseases 0.000 description 1
• 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
• 150000001299 aldehydes Chemical group 0.000 description 1
• HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 1
• SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
• 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 description 1
• 208000002205 allergic conjunctivitis Diseases 0.000 description 1
• 208000002029 allergic contact dermatitis Diseases 0.000 description 1
• 231100000360 alopecia Toxicity 0.000 description 1
• 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
• WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
• 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
• 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
• WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
• BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
• 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
• 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
• 235000011130 ammonium sulphate Nutrition 0.000 description 1
• 230000003444 anaesthetic effect Effects 0.000 description 1
• 208000003455 anaphylaxis Diseases 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 239000004037 angiogenesis inhibitor Substances 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 238000005571 anion exchange chromatography Methods 0.000 description 1
• 150000001450 anions Chemical class 0.000 description 1
• 210000002226 anterior horn cell Anatomy 0.000 description 1
• 201000004612 anterior uveitis Diseases 0.000 description 1
• 230000000507 anthelmentic effect Effects 0.000 description 1
• 230000000489 anti-atherogenic effect Effects 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 230000003510 anti-fibrotic effect Effects 0.000 description 1
• 230000000845 anti-microbial effect Effects 0.000 description 1
• 230000002682 anti-psoriatic effect Effects 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 230000000767 anti-ulcer Effects 0.000 description 1
• 229940124350 antibacterial drug Drugs 0.000 description 1
• 238000011091 antibody purification Methods 0.000 description 1
• 238000009175 antibody therapy Methods 0.000 description 1
• 230000009227 antibody-mediated cytotoxicity Effects 0.000 description 1
• 229940125714 antidiarrheal agent Drugs 0.000 description 1
• 229940125683 antiemetic agent Drugs 0.000 description 1
• 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
• 239000002216 antistatic agent Substances 0.000 description 1
• 229940121357 antivirals Drugs 0.000 description 1
• 210000000709 aorta Anatomy 0.000 description 1
• 210000000702 aorta abdominal Anatomy 0.000 description 1
• 208000007474 aortic aneurysm Diseases 0.000 description 1
• 206010002895 aortic dissection Diseases 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 239000003125 aqueous solvent Substances 0.000 description 1
• 235000019312 arabinogalactan Nutrition 0.000 description 1
• 229940114079 arachidonic acid Drugs 0.000 description 1
• 235000021342 arachidonic acid Nutrition 0.000 description 1
• 230000005988 arterial dysfunction Effects 0.000 description 1
• 208000037849 arterial hypertension Diseases 0.000 description 1
• 239000011668 ascorbic acid Chemical class 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
• 239000000605 aspartame Substances 0.000 description 1
• 235000010357 aspartame Nutrition 0.000 description 1
• 229960003438 aspartame Drugs 0.000 description 1
• 239000012131 assay buffer Substances 0.000 description 1
• 238000003149 assay kit Methods 0.000 description 1
• 206010003549 asthenia Diseases 0.000 description 1
• 208000024998 atopic conjunctivitis Diseases 0.000 description 1
• 230000001746 atrial effect Effects 0.000 description 1
• 206010003668 atrial tachycardia Diseases 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 239000005667 attractant Substances 0.000 description 1
• 210000000467 autonomic pathway Anatomy 0.000 description 1
• 208000033354 avian tuberculosis Diseases 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
• 239000000688 bacterial toxin Substances 0.000 description 1
• 210000004227 basal ganglia Anatomy 0.000 description 1
• 208000018300 basal ganglia disease Diseases 0.000 description 1
• 210000003651 basophil Anatomy 0.000 description 1
• OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• 229940116226 behenic acid Drugs 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 229960000686 benzalkonium chloride Drugs 0.000 description 1
• UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
• 229960001950 benzethonium chloride Drugs 0.000 description 1
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
• 229960003237 betaine Drugs 0.000 description 1
• XFLVBMBRLSCJAI-ZKWXMUAHSA-N biotin amide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)N)SC[C@@H]21 XFLVBMBRLSCJAI-ZKWXMUAHSA-N 0.000 description 1
• XFLVBMBRLSCJAI-UHFFFAOYSA-N biotin amide Natural products N1C(=O)NC2C(CCCCC(=O)N)SCC21 XFLVBMBRLSCJAI-UHFFFAOYSA-N 0.000 description 1
• OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 108010006025 bovine growth hormone Proteins 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 201000009267 bronchiectasis Diseases 0.000 description 1
• 206010006451 bronchitis Diseases 0.000 description 1
• 239000007853 buffer solution Substances 0.000 description 1
• 210000004375 bundle of his Anatomy 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical class O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 230000003185 calcium uptake Effects 0.000 description 1
• 238000004422 calculation algorithm Methods 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 230000002612 cardiopulmonary effect Effects 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 238000012219 cassette mutagenesis Methods 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 238000005277 cation exchange chromatography Methods 0.000 description 1
• 230000021164 cell adhesion Effects 0.000 description 1
• 238000013354 cell banking Methods 0.000 description 1
• 230000003833 cell viability Effects 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 208000025434 cerebellar degeneration Diseases 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 229960003115 certolizumab pegol Drugs 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 230000031902 chemoattractant activity Effects 0.000 description 1
• 239000002556 chemokine receptor agonist Substances 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 229960002242 chlorocresol Drugs 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 208000019069 chronic childhood arthritis Diseases 0.000 description 1
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
• 238000001142 circular dichroism spectrum Methods 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 235000015165 citric acid Nutrition 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 238000012761 co-transfection Methods 0.000 description 1
• 238000004581 coalescence Methods 0.000 description 1
• 239000000084 colloidal system Substances 0.000 description 1
• 238000010961 commercial manufacture process Methods 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 201000000464 cone-rod dystrophy 2 Diseases 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 238000007596 consolidation process Methods 0.000 description 1
• 208000010247 contact dermatitis Diseases 0.000 description 1
• 230000009519 contusion Effects 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 208000029078 coronary artery disease Diseases 0.000 description 1
• 210000004351 coronary vessel Anatomy 0.000 description 1
• 230000001054 cortical effect Effects 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 231100000599 cytotoxic agent Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 239000002619 cytotoxin Substances 0.000 description 1
• 229960003901 dacarbazine Drugs 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 208000017004 dementia pugilistica Diseases 0.000 description 1
• 230000003210 demyelinating effect Effects 0.000 description 1
• 201000002950 dengue hemorrhagic fever Diseases 0.000 description 1
• 238000000151 deposition Methods 0.000 description 1
• 239000003241 dermatological agent Substances 0.000 description 1
• 229940000033 dermatological agent Drugs 0.000 description 1
• 201000009803 desquamative interstitial pneumonia Diseases 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 208000033679 diabetic kidney disease Diseases 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 230000001079 digestive effect Effects 0.000 description 1
• OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 description 1
• 201000011304 dilated cardiomyopathy 1A Diseases 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
• 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
• PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
• 206010013023 diphtheria Diseases 0.000 description 1
• 208000037765 diseases and disorders Diseases 0.000 description 1
• 238000002224 dissection Methods 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 239000003596 drug target Substances 0.000 description 1
• 229940112141 dry powder inhaler Drugs 0.000 description 1
• 238000001035 drying Methods 0.000 description 1
• 239000000428 dust Substances 0.000 description 1
• 230000005684 electric field Effects 0.000 description 1
• 230000003073 embolic effect Effects 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 206010014665 endocarditis Diseases 0.000 description 1
• 210000003979 eosinophil Anatomy 0.000 description 1
• 201000010063 epididymitis Diseases 0.000 description 1
• 208000001606 epiglottitis Diseases 0.000 description 1
• 208000037828 epithelial carcinoma Diseases 0.000 description 1
• 201000011384 erythromelalgia Diseases 0.000 description 1
• 229930182833 estradiol Natural products 0.000 description 1
• 229960005309 estradiol Drugs 0.000 description 1
• 229960001842 estramustine Drugs 0.000 description 1
• FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
• HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
• 238000012869 ethanol precipitation Methods 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• 230000008020 evaporation Effects 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 239000002095 exotoxin Substances 0.000 description 1
• 231100000776 exotoxin Toxicity 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 210000003414 extremity Anatomy 0.000 description 1
• 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
• 239000010685 fatty oil Substances 0.000 description 1
• 238000000855 fermentation Methods 0.000 description 1
• 230000004151 fermentation Effects 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 206010016629 fibroma Diseases 0.000 description 1
• 201000008825 fibrosarcoma of bone Diseases 0.000 description 1
• 230000003890 fistula Effects 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 229960002074 flutamide Drugs 0.000 description 1
• MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 238000012395 formulation development Methods 0.000 description 1
• 230000037433 frameshift Effects 0.000 description 1
• 238000002825 functional assay Methods 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 229930182830 galactose Natural products 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 201000005917 gastric ulcer Diseases 0.000 description 1
• 238000012637 gene transfection Methods 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 108060003196 globin Proteins 0.000 description 1
• 239000000174 gluconic acid Chemical class 0.000 description 1
• 235000012208 gluconic acid Nutrition 0.000 description 1
• 102000005396 glutamine synthetase Human genes 0.000 description 1
• 108020002326 glutamine synthetase Proteins 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• 150000002333 glycines Chemical class 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 150000002337 glycosamines Chemical group 0.000 description 1
• 229960002913 goserelin Drugs 0.000 description 1
• 208000024908 graft versus host disease Diseases 0.000 description 1
• 238000005469 granulation Methods 0.000 description 1
• 230000003179 granulation Effects 0.000 description 1
• 238000001631 haemodialysis Methods 0.000 description 1
• 201000009277 hairy cell leukemia Diseases 0.000 description 1
• 208000024348 heart neoplasm Diseases 0.000 description 1
• 208000018578 heart valve disease Diseases 0.000 description 1
• 201000011066 hemangioma Diseases 0.000 description 1
• 208000014951 hematologic disease Diseases 0.000 description 1
• 208000018706 hematopoietic system disease Diseases 0.000 description 1
• 230000000322 hemodialysis Effects 0.000 description 1
• 230000002949 hemolytic effect Effects 0.000 description 1
• 125000005842 heteroatom Chemical group 0.000 description 1
• RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 1
• 239000000710 homodimer Substances 0.000 description 1
• 210000003917 human chromosome Anatomy 0.000 description 1
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
• 150000005828 hydrofluoroalkanes Chemical class 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
• 208000013403 hyperactivity Diseases 0.000 description 1
• 230000000148 hypercalcaemia Effects 0.000 description 1
• 208000030915 hypercalcemia disease Diseases 0.000 description 1
• 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
• 229960003685 imatinib mesylate Drugs 0.000 description 1
• YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 229940124622 immune-modulator drug Drugs 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 230000002584 immunomodulator Effects 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 238000000126 in silico method Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 208000000509 infertility Diseases 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 208000021267 infertility disease Diseases 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 208000037797 influenza A Diseases 0.000 description 1
• CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
• 229960000367 inositol Drugs 0.000 description 1
• 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 229940036646 iodine-131-tositumomab Drugs 0.000 description 1
• 230000005865 ionizing radiation Effects 0.000 description 1
• 229960004768 irinotecan Drugs 0.000 description 1
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 201000004815 juvenile spinal muscular atrophy Diseases 0.000 description 1
• 238000012933 kinetic analysis Methods 0.000 description 1
• 238000012004 kinetic exclusion assay Methods 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 239000000832 lactitol Substances 0.000 description 1
• 235000010448 lactitol Nutrition 0.000 description 1
• VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
• 229960003451 lactitol Drugs 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 201000010901 lateral sclerosis Diseases 0.000 description 1
• 239000002523 lectin Substances 0.000 description 1
• 229940087875 leukine Drugs 0.000 description 1
• GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
• 229960004338 leuprorelin Drugs 0.000 description 1
• 210000004558 lewy body Anatomy 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 231100000053 low toxicity Toxicity 0.000 description 1
• 235000020121 low-fat milk Nutrition 0.000 description 1
• 201000003453 lung abscess Diseases 0.000 description 1
• 208000037841 lung tumor Diseases 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 208000002502 lymphedema Diseases 0.000 description 1
• 208000005158 lymphoid interstitial pneumonia Diseases 0.000 description 1
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 208000002780 macular degeneration Diseases 0.000 description 1
• 239000006249 magnetic particle Substances 0.000 description 1
• 235000009973 maize Nutrition 0.000 description 1
• 201000004792 malaria Diseases 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 201000006812 malignant histiocytosis Diseases 0.000 description 1
• 239000000845 maltitol Substances 0.000 description 1
• 235000010449 maltitol Nutrition 0.000 description 1
• VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
• 229940035436 maltitol Drugs 0.000 description 1
• 229940035034 maltodextrin Drugs 0.000 description 1
• 210000005075 mammary gland Anatomy 0.000 description 1
• 229960001855 mannitol Drugs 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
• 230000009245 menopause Effects 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 239000004005 microsphere Substances 0.000 description 1
• 206010027599 migraine Diseases 0.000 description 1
• OBBCSXFCDPPXOL-UHFFFAOYSA-N misonidazole Chemical compound COCC(O)CN1C=CN=C1[N+]([O-])=O OBBCSXFCDPPXOL-UHFFFAOYSA-N 0.000 description 1
• 229950010514 misonidazole Drugs 0.000 description 1
• 108091064355 mitochondrial RNA Proteins 0.000 description 1
• 230000002438 mitochondrial effect Effects 0.000 description 1
• 239000011812 mixed powder Substances 0.000 description 1
• 230000003020 moisturizing effect Effects 0.000 description 1
• 230000004001 molecular interaction Effects 0.000 description 1
• 150000002763 monocarboxylic acids Chemical class 0.000 description 1
• 230000028550 monocyte chemotaxis Effects 0.000 description 1
• 208000005264 motor neuron disease Diseases 0.000 description 1
• 208000017972 multifocal atrial tachycardia Diseases 0.000 description 1
• 229940035363 muscle relaxants Drugs 0.000 description 1
• 230000000869 mutational effect Effects 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 239000002637 mydriatic agent Substances 0.000 description 1
• 206010028537 myelofibrosis Diseases 0.000 description 1
• 230000002107 myocardial effect Effects 0.000 description 1
• 208000002089 myocardial stunning Diseases 0.000 description 1
• 239000002105 nanoparticle Substances 0.000 description 1
• 239000002077 nanosphere Substances 0.000 description 1
• 150000002790 naphthalenes Chemical class 0.000 description 1
• 239000007923 nasal drop Substances 0.000 description 1
• 229940100662 nasal drops Drugs 0.000 description 1
• 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
• 208000009928 nephrosis Diseases 0.000 description 1
• 231100001027 nephrosis Toxicity 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 208000015122 neurodegenerative disease Diseases 0.000 description 1
• 201000004931 neurofibromatosis Diseases 0.000 description 1
• 210000005044 neurofilament Anatomy 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• 229960002653 nilutamide Drugs 0.000 description 1
• XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
• OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
• 108091027963 non-coding RNA Proteins 0.000 description 1
• 102000042567 non-coding RNA Human genes 0.000 description 1
• 239000002687 nonaqueous vehicle Substances 0.000 description 1
• 239000002736 nonionic surfactant Substances 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 210000004940 nucleus Anatomy 0.000 description 1
• 208000014055 occupational lung disease Diseases 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 239000002751 oligonucleotide probe Substances 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 201000005737 orchitis Diseases 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 229920000620 organic polymer Polymers 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 238000012261 overproduction Methods 0.000 description 1
• 239000007800 oxidant agent Substances 0.000 description 1
• 239000003002 pH adjusting agent Substances 0.000 description 1
• 210000002741 palatine tonsil Anatomy 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 230000001769 paralizing effect Effects 0.000 description 1
• 208000012111 paraneoplastic syndrome Diseases 0.000 description 1
• 230000003071 parasitic effect Effects 0.000 description 1
• 230000000849 parathyroid Effects 0.000 description 1
• 230000001314 paroxysmal effect Effects 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• 206010034674 peritonitis Diseases 0.000 description 1
• 230000008782 phagocytosis Effects 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 229940127557 pharmaceutical product Drugs 0.000 description 1
• 239000008180 pharmaceutical surfactant Substances 0.000 description 1
• 230000003285 pharmacodynamic effect Effects 0.000 description 1
• ORMNNUPLFAPCFD-DVLYDCSHSA-M phenethicillin potassium Chemical compound [K+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C(C)OC1=CC=CC=C1 ORMNNUPLFAPCFD-DVLYDCSHSA-M 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• 229940080469 phosphocellulose Drugs 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 125000002743 phosphorus functional group Chemical group 0.000 description 1
• 238000005222 photoaffinity labeling Methods 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 208000024356 pleural disease Diseases 0.000 description 1
• 201000000317 pneumocystosis Diseases 0.000 description 1
• 231100000572 poisoning Toxicity 0.000 description 1
• 230000000607 poisoning effect Effects 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 229940116406 poloxamer 184 Drugs 0.000 description 1
• 229940044519 poloxamer 188 Drugs 0.000 description 1
• 229920001993 poloxamer 188 Polymers 0.000 description 1
• 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
• 229920001308 poly(aminoacid) Polymers 0.000 description 1
• 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
• 229920001515 polyalkylene glycol Polymers 0.000 description 1
• 229920002647 polyamide Polymers 0.000 description 1
• 108010011110 polyarginine Proteins 0.000 description 1
• 108010064470 polyaspartate Proteins 0.000 description 1
• 229920000728 polyester Polymers 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
• 230000007824 polyneuropathy Effects 0.000 description 1
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
• 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 229940068977 polysorbate 20 Drugs 0.000 description 1
• 229940068968 polysorbate 80 Drugs 0.000 description 1
• 229940068965 polysorbates Drugs 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 201000011461 pre-eclampsia Diseases 0.000 description 1
• 230000002028 premature Effects 0.000 description 1
• 108010066381 preproinsulin Proteins 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 150000003141 primary amines Chemical class 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 201000008312 primary pulmonary hypertension Diseases 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000006239 protecting group Chemical group 0.000 description 1
• 230000004845 protein aggregation Effects 0.000 description 1
• 229940076372 protein antagonist Drugs 0.000 description 1
• 230000012846 protein folding Effects 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 230000004850 protein–protein interaction Effects 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 208000005069 pulmonary fibrosis Diseases 0.000 description 1
• 201000003456 pulmonary hemosiderosis Diseases 0.000 description 1
• 201000003651 pulmonary sarcoidosis Diseases 0.000 description 1
• 230000010349 pulsation Effects 0.000 description 1
• 239000012264 purified product Substances 0.000 description 1
• HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
• 238000012207 quantitative assay Methods 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000014493 regulation of gene expression Effects 0.000 description 1
• 229940116176 remicade Drugs 0.000 description 1
• 201000002793 renal fibrosis Diseases 0.000 description 1
• 230000001850 reproductive effect Effects 0.000 description 1
• 201000004193 respiratory failure Diseases 0.000 description 1
• 150000004492 retinoid derivatives Chemical class 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 210000003705 ribosome Anatomy 0.000 description 1
• 238000002702 ribosome display Methods 0.000 description 1
• 229960004641 rituximab Drugs 0.000 description 1
• 102220214819 rs754231971 Human genes 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 238000013341 scale-up Methods 0.000 description 1
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
• 201000001223 septic arthritis Diseases 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 229940007046 shigella dysenteriae Drugs 0.000 description 1
• 229940115939 shigella sonnei Drugs 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 208000007056 sickle cell anemia Diseases 0.000 description 1
• 239000002356 single layer Substances 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 239000003998 snake venom Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 229940083542 sodium Drugs 0.000 description 1
• 239000007974 sodium acetate buffer Substances 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 229940054269 sodium pyruvate Drugs 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 238000000638 solvent extraction Methods 0.000 description 1
• 230000003595 spectral effect Effects 0.000 description 1
• 238000010183 spectrum analysis Methods 0.000 description 1
• 208000002320 spinal muscular atrophy Diseases 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 230000010473 stable expression Effects 0.000 description 1
• 239000012086 standard solution Substances 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 239000011550 stock solution Substances 0.000 description 1
• 238000012916 structural analysis Methods 0.000 description 1
• 238000005556 structure-activity relationship Methods 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
• 229960001940 sulfasalazine Drugs 0.000 description 1
• NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
• 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 206010042772 syncope Diseases 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 230000006794 tachycardia Effects 0.000 description 1
• 229960001603 tamoxifen Drugs 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 239000011975 tartaric acid Chemical class 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 208000009056 telangiectasis Diseases 0.000 description 1
• 229960004964 temozolomide Drugs 0.000 description 1
• AOCSUUGBCMTKJH-UHFFFAOYSA-N tert-butyl n-(2-aminoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCN AOCSUUGBCMTKJH-UHFFFAOYSA-N 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• 229960003604 testosterone Drugs 0.000 description 1
• CWXZMNMLGZGDSW-UHFFFAOYSA-N tetracontanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O CWXZMNMLGZGDSW-UHFFFAOYSA-N 0.000 description 1
• UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 1
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
• 150000004044 tetrasaccharides Chemical class 0.000 description 1
• WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 229940124598 therapeutic candidate Drugs 0.000 description 1
• 238000011287 therapeutic dose Methods 0.000 description 1
• 230000008719 thickening Effects 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• 206010043554 thrombocytopenia Diseases 0.000 description 1
• 210000001541 thymus gland Anatomy 0.000 description 1
• 206010043778 thyroiditis Diseases 0.000 description 1
• ORYDPOVDJJZGHQ-UHFFFAOYSA-N tirapazamine Chemical compound C1=CC=CC2=[N+]([O-])C(N)=N[N+]([O-])=C21 ORYDPOVDJJZGHQ-UHFFFAOYSA-N 0.000 description 1
• 229950002376 tirapazamine Drugs 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 231100000827 tissue damage Toxicity 0.000 description 1
• 230000009772 tissue formation Effects 0.000 description 1
• 208000037816 tissue injury Diseases 0.000 description 1
• 230000017423 tissue regeneration Effects 0.000 description 1
• 230000007838 tissue remodeling Effects 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
• 230000005026 transcription initiation Effects 0.000 description 1
• 238000001890 transfection Methods 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000014621 translational initiation Effects 0.000 description 1
• 230000005945 translocation Effects 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 229960001727 tretinoin Drugs 0.000 description 1
• VHOCUJPBKOZGJD-UHFFFAOYSA-N triacontanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O VHOCUJPBKOZGJD-UHFFFAOYSA-N 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 150000004043 trisaccharides Chemical class 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 229940073585 tromethamine hydrochloride Drugs 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
• 208000025883 type III hypersensitivity disease Diseases 0.000 description 1
• 230000005951 type IV hypersensitivity Effects 0.000 description 1
• 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 208000009852 uremia Diseases 0.000 description 1
• 230000002485 urinary effect Effects 0.000 description 1
• 208000027185 varicose disease Diseases 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 238000007879 vasectomy Methods 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 239000002435 venom Substances 0.000 description 1
• 231100000611 venom Toxicity 0.000 description 1
• 210000001048 venom Anatomy 0.000 description 1
• 208000037997 venous disease Diseases 0.000 description 1
• 229940070384 ventolin Drugs 0.000 description 1
• 208000003663 ventricular fibrillation Diseases 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 201000002498 viral encephalitis Diseases 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 239000011534 wash buffer Substances 0.000 description 1
• 239000002023 wood Substances 0.000 description 1